Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial



Summary

This phase 1 clinical trial investigated the safety and efficacy of intracerebroventricular (ICV) administration of bivalent CAR T cells targeting EGFR and IL-13Rα2 in patients with recurrent glioblastoma (rGBM). The CAR T cells were engineered to recognize two GBM-associated antigens, potentially improving tumor targeting and overcoming antigen escape. Preliminary results suggested the treatment was generally well-tolerated, with manageable toxicities. Some patients showed evidence of clinical benefit, including tumor regression or stabilization. This study provides initial evidence for the feasibility and potential of this novel CAR T cell therapy for rGBM and warrants further investigation.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!